Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +972-77-2005042 from 8 AM - 11 PM IL

      • Contact
      • Contact

        +972-77-2005042
        from 8 AM - 11 PM IL

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Request More Information
      • Journalists
      • GDPR

      Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

      Check-Cap Logo

      News provided by

      Check-Cap Ltd.

      31 Aug, 2022, 15:00 IDT

      Share this article

      Share this article


      ISFIYA, Israel, Aug. 31, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results and provided a corporate update for the second quarter and six months ended June 30, 2022.

      Second Quarter and Recent Highlights:

      • Initiated the first part of the U.S. pivotal study of C-Scan, that focuses on device calibration and enhancement of C-Scan algorithms among the average risk U.S. population, at Mayo Clinic in Rochester, Minnesota and New York University (NYU) School of Medicine. In parallel, Check-Cap is also enrolling average risk patients in Israel, to further optimize C-Scan functionality and patient experience. The required lead time to activate new sites as well as to recruit patients in the U.S. has been longer than expected. The Company is continuing to work on activating new sites while at the same time calibrating the C-Scan device and its algorithms. Assuming sites' activation and calibration proceeds as planned, the Company expects the second part of the U.S. pivotal study to start in mid-2023.
      • Nominated Aasma Shaukat, M.D., MPH, a Robert M. and Mary H. Glickman Professor of Gastroenterology and Professor of Population Health, Director of Gastroenterology Outcomes Research at NYU Grossman School of Medicine, as Coordinating Principal Investigator (CPI) for the pivotal study. Dr. Aasma brings two decades of experience as a practicing gastroenterologist and clinical researcher with expertise in colon cancer screening, long term outcomes and colorectal cancer non-invasive screening. She is a member of the U.S. Multi-society Task Force on Colorectal Cancer (USMSTF) and was first author of the American College of Gastroenterology (ACG) clinical guideline on Colorectal cancer screening in 2021.
      • On August 11, 2022, the Company's shareholders approved a reverse share split of the Company's ordinary shares within a range of 1 for 10 to 1 for 20, with the exact ratio and effective date to be determined by further action of the Company's Board of Directors, and to be announced by the company. 

      "Since initiation of the pivotal trial in May 2022 we have been diligently working to expand patient enrollment and data collection," said Alex Ovadia, chief executive officer of Check-Cap." The team is focused on achieving our study objectives and we intend to provide updates in the coming months. We are also pleased to welcome Dr. Shaukat as Coordinating Principal Investigator. Her extensive clinical experience and involvement in the colorectal cancer screening field will be extremely valuable as we continue to advance the study."

      Financial Results for the Second Quarter Ended June 30, 2022

      Research and development expenses were $3.5 million for the three months ended June 30, 2022, compared to $2.8 million for the same period in 2021. The increase is primarily due to (i) an increase of approximately $0.4 million in salary and related expenses, mainly as a result of increased employee head count, and (ii) an increase of approximately $0.3 million in other research and development expenses, including clinical related expenses and regulatory consultants.  The Company expects that clinical related expenses will increase in the upcoming quarters as it progresses in its ongoing U.S. pivotal study.

      General and administrative expenses were $1.3 million for the three months ended June 30, 2022, compared to $1.1 million for the same period in 2021. The increase is primarily due to a $0.1 million increase in other general expenses, mainly associated with directors' and officers' liability insurance, and a $0.1 million increase in share-based compensation. 

      Operating loss was $4.9 million for the three months ended June 30, 2022, compared to $3.9 million for the same period in 2021.

      Net finance income was $81,000 for the three months ended June 30, 2022, compared to $5,000 for the same period in 2021.

      Net loss was $4.8 million for the three months ended June 30, 2022, compared to $3.9 million for the same period in 2021.

      Cash and cash equivalents, restricted cash and short-term bank deposits as of June 30, 2022 were $50.2 million, compared with $55.7 million as of March 31, 2022 and $51.9 million as of December 31, 2021.  On March 3, 2022, the Company consummated a registered direct offering for the sale of 20,000,000 of the Company's ordinary shares and accompanying warrants to purchase up to an aggregate of 15,000,000 of the Company's ordinary shares. The registered direct offering resulted in gross proceeds to the Company of $10.0 million or approximately $8.9 million net of offering expenses. The Company believes that it has sufficient capital to fund its ongoing operations and plans into the second quarter of 2024.

      Financial Results for the Six Months Ended June 30, 2022

      Research and development expenses were $7.7 million for the six months ended June 30, 2022, compared to $5.2 million for the same period in 2021. The increase is primarily due to (i) an increase of approximately $1.2 million in salary and related expenses, mainly as a result of increased employee head count, (ii) an increase of approximately $0.8 million in other research and development expenses, including clinical related expenses and regulatory consultants and (iii) an increase of approximately $0.2 million in share-based compensation.  The increase in net research and development expenses between 2022 and 2021 is also due to a $0.3 million grant from the Israel Innovation Authority, which amount was recorded as a deduction from research and development expenses in the six months ended June 30, 2021.

      General and administrative expenses were $3.1 million for the six months ended June 30, 2022, compared to $2.3 million for the same period in 2021. The increase is primarily due to a $0.4 million increase in professional services, a $0.2 million increase in other general expenses, mainly associated with directors' and officers' liability insurance, and a $0.2 million increase in share-based compensation. 

      Operating loss was $10.8 million for the six months ended June 30, 2022, compared to $7.5 million for the same period in 2021.

      Net finance income was $132,000 for the six months ended June 30, 2022, compared to finance loss of $4,000 for the same period in 2021.

      Net loss was $10.6 million for the six months ended June 30, 2022, compared to $7.5 million for the same period in 2021.

      Net cash used in operating activities was $10.3 million for the six months ended June 30, 2022, compared to $7.8 million for the same period in 2021.

      About Check-Cap

      Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. It requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy.  C-Scan is an investigational device and is not available for sale in the United States.

      Legal Notice Regarding Forward-Looking Statements

      This press release contains "forward-looking statements" about the Company's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise

      Investor Contacts
      Irina Koffler 
      LifeSci Advisors, LLC 
      646.970.4681
      [email protected]

      Meirav Gomeh-Bauer
      LifeSci Advisors, LLC 
      +972(0)-54-476-4979
      [email protected]

      Media Contact
      Mónica Rouco Molina, Ph.D.
      Account Supervisor - Europe
      LifeSci Communications
      [email protected]

      CHECK CAP LTD

      CONSOLIDATED UNAUDITED BALANCE SHEETS

      (U.S. dollars in thousands, except share and per share data)




      June 30,



      December 31,




      2022



      2021




       Unaudited



       Audited


      Assets














      Current assets







      Cash and cash equivalents


      $

      11,637



      $

      26,457


      Restricted cash



      351




      350


      Short-term bank deposit



      38,206




      25,104


      Prepaid expenses and other current assets



      996




      839


      Total current assets



      51,190




      52,750











      Non-current assets









      Property and equipment, net



      1,836




      1,793


      Operating leases



      1,100




      1,116


      Total non-current assets



      2,936




      2,909


      Total assets


      $

      54,126



      $

      55,659











      Liabilities and shareholders' equity


















      Current liabilities









      Accounts payable and accruals









      Trade


      $

      946



      $

      1,050


      Other



      701




      680


      Employees and payroll accruals



      1,668




      1,961


      Other current liabilities



      279




      -


      Operating lease liabilities



      332




      350


      Total current liabilities



      3,926




      4,041











      Non-current liabilities









      Royalties provision



      107




      132


      Operating lease liabilities



      669




      795


      Total non-current liabilities



      776




      927











      Shareholders' equity









      Share capital, Ordinary shares, 2.4 NIS par value (360,000,000 authorized shares as of June 30, 2022 and December









      31, 2021, respectively; 116,411,949 and 96,411,949 shares issued and outstanding as of June 30, 2022 and December









      31, 2021, respectively)



      83,602




      68,787


      Additional paid-in capital



      84,648




      90,089


      Accumulated deficit



      (118,826)




      (108,185)


      Total shareholders' equity



      49,424




      50,691











      Total liabilities and shareholders' equity


      $

      54,126



      $

      55,659


      CHECK CAP LTD 


      CONSOLIDATED UNAUDITED STATEMENTS OF COMPREHENSIVE LOSS


      (U.S. dollars in thousands, except share and per share data)






      Six months ended June 30,



      Three months ended June 30,




      2022



      2021



      2022



      2021















      Research and development expenses, net


      $

      7,673



      $

      5,187



      $

      3,545



      $

      2,781


      General and administrative expenses



      3,100




      2,293




      1,343




      1,142


      Operating loss



      10,773




      7,480




      4,888




      3,923



















      Finance Income (loss), net



      132




      (4)




      81




      5


      Loss before income tax



      10,641




      7,484




      4,807




      3,918



















      Net loss for the period


      $

      10,641



      $

      7,484



      $

      4,807



      $

      3,918


      Loss per share:

















      Net loss per ordinary share basic and diluted


      $

      0.10



      $

      0.11



      $

      0.04



      $

      0.06



















      Weighted average number of ordinary shares outstanding - basic and diluted



      109,561,120




      69,284,917




      116,411,949




      70,485,435


      CHECK CAP LTD.




      CONSOLIDATED UNAUDITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY




      (U.S. dollars in thousands, except share and per share data)










      Number of




      Additional




      Total






      Ordinary




      paid-in


      Accumulated


      shareholders'






      Shares


      Amount


      capital


      deficit


      equity


















      Balance as of January 1, 2022



      96,411,949


      $

      68,787


      $

      90,089


      $

      (108,185)


      $

      50,691




      Issuance of ordinary
      shares in registered
      direct offerings
      , net of
      issuance expenses in an
      amount



















      of $1,150



      20,000,000



      14,815



      (5,965)



      -



      8,850




      Share-based compensation



      -



      -



      250



      -



      250




      Net loss



      -



      -



      -



      (5,834)



      (5,834)




      Balance as of March 31, 2022



      116,411,949


      $

      83,602


      $

      84,374


      $

      (114,019)


      $

      53,957




      Share-based compensation



      -



      -



      274



      -



      274




      Net loss



      -



      -



      -



      (4,807)



      (4,807)




      Balance as of June 30, 2022



      116,411,949


      $

      83,602


      $

      84,648


      $

      (118,826)


      $

      49,424




      Balance as of January 1, 2021


      46,239,183


      $

      31,646


      $

      75,715


      $

      (90,983)


      $

      16,378


      Exercise of warrants,
      net of issuance expenses
      in
















      an amount of $22


      24,204,682



      18,099



      1,120



      -



      19,219


      RSUs vesting


      24,395



      18



      (18)



      -



      -


      Share-based compensation


      -



      -



      73



      -



      73


      Net loss


      -



      -



      -



      (3,566)



      (3,566)


      Balance as of March 31, 2021


      70,468,260


      $

      49,763


      $

      76,890


      $

      (94,549)


      $

      32,104


      RSUs vesting


      5,381



      4



      (4)



      -



      -


      Share-based compensation


      -



      -



      65



      -



      65


      Net loss


      -



      -



      -



      (3,918)



      (3,918)


















      Balance as of June 30, 2021


      70,473,641


      $

      49,767


      $

      76,951


      $

      (98,467)


      $

      28,251


      CHECK-CAP LTD.

      CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS

      (U.S. dollars in thousands, except share and per share data)




      Six months ended




      June 30,




      2022



      2021


      CASH FLOWS FROM OPERATING ACTIVITIES







      Net loss


      $

      (10,641)



      $

      (7,484)


      Adjustments required to reconcile net loss to net cash used in operating activities:









      Depreciation



      159




      89


      Share-based compensation



      525




      138


      Financial income, net



      (239)




      (36)


      Changes in assets and liabilities items:









      Increase in prepaid and other current assets and non-current assets



      (152)




      (508)


      Increase in trade accounts payable, accruals and other current liabilities



      320




      27


      Decrease in employees and payroll accruals



      (293)




      (62)


      (Decrease) increase in royalties provision



      (25)




      35


      Net cash used in operating activities


      $

      (10,346)



      $

      (7,801)











      CASH FLOWS FROM INVESTING ACTIVITIES









      Purchase of property and equipment



      (323)




      (218)


      Investment in short-term bank and other deposits



      (13,000)




      (8,814)


      Net cash used in investing activities


      $

      (13,323)



      $

      (9,032)











      CASH FLOWS FROM FINANCING ACTIVITIES









      Exercise of warrants into ordinary shares, net of issuance expenses



      —




      19,219


      Issuance of ordinary shares in the registered direct offerings, net of issuance expenses



      8,850




      —


      Net cash provided by financing activities


      $

      8,850



      $

      19,219











      Net increase in cash, cash equivalents and restricted cash



      (14,819)




      2,386


      Cash, cash equivalents and restricted cash at the beginning of the period



      26,807




      8,053


      Cash, cash equivalents and restricted cash at the end of the period


      $

      11,988



      $

      10,439






















      Six months ended

      June 30,



      2022



      2021


      Supplemental disclosure of non-cash flow information







      Purchase of property and equipment included in accounts payable and accrued expenses



      38



      59


      Financing fees included in other account payable and accruals



      —



      291


      Assets acquired under operating lease



      167



      916


















      Supplemental disclosure of cash flow information:







      Cash paid for taxes



      3




      7


      Interest received



      138




      24


      SOURCE Check-Cap Ltd.

      Modal title

      Contact PR Newswire

      • +972-77-2005042
        from 8 AM - 11 PM IL

      Global Sites

      • APAC
      • APAC - Traditional Chinese
      • Asia
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany

       

      • India
      • Indonesia
      • Israel
      • Italy
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland

       

      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921
      Global Sites
      • Asia
      • Brazil
      • Canada
      • Csezh
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Israel
      • Italie
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      +972-77-2005042
      from 8 AM - 11 PM IL
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • Cookie Settings
      Copyright © 2026 Cision US Inc.